Prime Medicine (NASDAQ:PRME) Stock Falls 7.6% – What’s Next?

Prime Medicine, Inc. (NASDAQ:PRME – Get Free Report) dropped 7.6% during mid-day trading on Tuesday. The company traded as low as $3.90 and last traded at $3.8710. 3,077,519 shares were traded during mid-day trading, a decline of 9% from the average session volume of 3,391,353 shares. The stock had previously closed at $4.19.

Recent Prime Medicine Headlines

Investors following PRME have been watching these headlines:

  • Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to a loss of $0.99 per share from $1.11, and modestly improved estimates for FY2027–FY2030 and several quarterly periods. The analyst reaffirmed a Buy rating and an $8 price target, a supportive signal for investor sentiment, though Prime Medicine is still expected to report losses. HC Wainwright estimate changes Buy rating reaffirmed
  • Neutral Sentiment: Prime Medicine presented at the Jefferies Global Healthcare Conference on November 16. The available report is a transcript listing and provides no specific announcements to assess as a stock catalyst. Jefferies conference transcript

Analyst Ratings Changes

PRME has been the topic of several analyst reports. Chardan Capital reiterated a “buy” rating and set a $7.00 price target on shares of Prime Medicine in a report on Friday, September 25th. HC Wainwright restated a “buy” rating and set a $8.00 price target on shares of Prime Medicine in a research note on Monday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Prime Medicine in a report on Monday, August 31st. Wall Street Zen upgraded Prime Medicine from a “sell” rating to a “hold” rating in a research report on Saturday, October 31st. Finally, Jefferies Financial Group restated a “market outperform” rating on shares of Prime Medicine in a research report on Monday, September 28th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Prime Medicine currently has an average rating of “Moderate Buy” and a consensus price target of $7.86.

Get Our Latest Analysis on PRME

Prime Medicine Trading Up 0.5%

The company has a market cap of $698.58 million, a price-to-earnings ratio of -4.00 and a beta of 2.14. The stock has a 50 day moving average price of $3.72 and a two-hundred day moving average price of $3.51.

Prime Medicine (NASDAQ:PRME – Get Free Report) last posted its earnings results on Thursday, November 12th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.01. The company had revenue of $4.21 million during the quarter. Prime Medicine had a negative return on equity of 222.88% and a negative net margin of 2,497.56%. On average, equities analysts forecast that Prime Medicine, Inc. will post -0.95 EPS for the current fiscal year.

Hedge Funds Weigh In On Prime Medicine

Several institutional investors and hedge funds have recently modified their holdings of PRME. Mirae Asset Global Investments Co. Ltd. bought a new position in Prime Medicine during the 3rd quarter worth about $28,000. Royal Bank of Canada lifted its stake in Prime Medicine by 89.3% in the 1st quarter. Royal Bank of Canada now owns 9,254 shares of the company’s stock valued at $32,000 after purchasing an additional 4,365 shares during the last quarter. Wealthfront Advisers LLC acquired a new stake in shares of Prime Medicine in the first quarter valued at approximately $36,000. Kingsview Wealth Management LLC acquired a new stake in Prime Medicine during the 2nd quarter valued at $37,000. Finally, Sequoia Financial Advisors LLC bought a new stake in shares of Prime Medicine during the 1st quarter worth about $41,000. 70.37% of the stock is currently owned by institutional investors and hedge funds.

Prime Medicine Company Profile

(Get Free Report)

Prime Medicine is a biotechnology company developing genetic therapies for diseases caused by genetic mutations. Its research focuses on prime editing, a gene-editing technology designed to make targeted changes to DNA, including substitutions, insertions and deletions. The company is working to apply its platform to potential treatments for a range of serious conditions. Its programs are in development, and Prime Medicine does not currently market approved therapies. Founded in 2019, Prime Medicine is based in Cambridge, Massachusetts.

Featured Stories

Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with MarketBeat.com's FREE daily email newsletter.